The intent of this study was to examine the health status of individuals who had been confirmed with COVID-19 in the year after their recovery. Parameters studied included serum levels of SARS coronavirus 2 (SARS-CoV 2) IgG antibody, SARS-CoV-2 nucleic acid test, hematology indicators (blood routine, liver function, kidney function, myocardial enzymes, coagulation function, etc), lung function test, imaging data and airway microbiota data. In addition, we explored the systematic Immune & Inflammation in some of the individuals recovering from COVID-19.
About 20% of COVID-19 developed into a critical illness and about 2% died. The global
epidemic continues to develop, but some patients in China have entered the rehabilitation
period, which is accompanied by a large number of respiratory symptoms and pulmonary
fibrosis, bringing serious harm to the country. Therefore, early accurate detection and
prediction of the development trend of patients in rehabilitation period and targeted
treatment measures for corresponding patients are the key to the success of COVID-19
rehabilitation period. It will play a key role in the stratified management of the
post-epidemic situation, which is crucial to improve the quality of life of COVID-19
patients. We aim to explore the clinical characteristics of rehabilitation patients by
detecting some indicators of patients in rehabilitation period, including serum IgG and IgM
antibody of SARS-CoV 2, SARS-CoV-2 nucleic acid, hematology indicators (blood routine, liver
function, kidney function, myocardial enzymes, coagulation function, etc), pulmonary
function, chest CT imaging, systematic Immune & Inflammation states.
Inclusion Criteria:
1. Individuals recovering from COVID-19, or asymptomatic COVID-19 patients with
laboratory test for SRARS-COV2 turning negative, or healthy volunteers without
COVID-19.
2. The age range is 18-80 years.
3. Subjects or their family members agree to participate in the study and sign informed
consent.
4. The previously diagnosed individuals have been cured for about 1 month.
Exclusion Criteria:
1. Woman who is breastfeeding, pregnant, or preparing to become pregnant.
2. Patients with cognitive impairment or poor compliance as determined by the
investigator.
3. Participants in other clinical trials.
4. Subjects who were not suitable for clinical trials determined by the investigator.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Investigator: Yang Jin, MD
Juanjuan Xu, professor
15972930101
whuhjy@126.com
Yang Jin, professor, Principal Investigator
Wuhan Union Hospital, China